Skip to content

Algorithms to Diagnose Pulmonary Arterial Hypertension

Development and Validation of a Radiomics-based Diagnosis Model for Pulmonary Arterial Hypertension

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05417373
Enrollment
250
Registered
2022-06-14
Start date
2019-01-17
Completion date
2023-06-01
Last updated
2022-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension

Keywords

Pulmonary Arterial Hypertension, Diagnosis Model, Prediction Algorithm

Brief summary

The investigators intend to evalute the value of radiomics signature of pulmonary vessels from chest computed tomography (CT) for dianosis and prognosis of pulmonary arterial hypertension.

Detailed description

Pulmonary arterial hypertension (PAH) is a heterogeneous disorder composed of varying pathobiology that may involve multiple clinical conditions. Computed tomography (CT) is a minimally invasive imaging technique capable of providing both high contrast and high resolution detail of the lungs and arteries. Application of radiomics as prognosis and diagnosis tools could quantifies high-dimensional features from CT data to investigate vescualr heterogeneity.Development and validation of PAH diagnosis Algorithms based on radiomics may serve as a complementary readout to current CT-based metrics and provide valuable evidence to make the treatment management decision in early PAH.

Interventions

OTHERcalculated radscore

The development cohort is case\_control research. The validation cohort is prospective study to test the accuracy of calculated radscore based on diagonisis model.

Sponsors

Shanghai Zhongshan Hospital
CollaboratorOTHER
The First Affiliated Hospital with Nanjing Medical University
CollaboratorOTHER
Xinqiao Hospital of Chongqing
CollaboratorOTHER
Shanghai Pulmonary Hospital, Shanghai, China
CollaboratorOTHER
RenJi Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Chest CT examination and cardiac ultrasound examination were performed within 3 months before and after right heart catheterization; 2. mPAP \> 25mmHg and PVR\< 3woods (measured by right heart catheter) and pulmonary vascular resistance was collected as PAH group whereas Healthy Volunteers as non-PAH control group in developement corhort; 3. sPAP \> 36mmHg (measured by echocardiography) was collected in validation corhort.

Exclusion criteria

1.Cancer; 2. The quality of chest CT and cardiac ultrasound images is poor; 3.Pulmonary vascular segmentation is affected by thoracic organ displacement or pulmonary vascular complete occlusion due to diseases ,such as spinal deformity.

Design outcomes

Primary

MeasureTime frameDescription
DIAGONOSIS1 yearThe patient is diagnosed PAH or not by right heart catheter

Countries

China

Contacts

Primary ContactJieyan Shen, PhD
shenjieyan@renji.com13701864819

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026